KMT2A and acute lymphoblastic leukemia: KMT2A rearrangement is the prototypical cytogenetic finding among tr-AML patients exposed to topoisomerase II inhibitors, and the incidence of KMT2A rearrangement is higher in tr-ALL compared to dn-ALL 4,6.